Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking bax translocation

被引:60
作者
Kim, M
Park, SY
Pai, HS
Kim, TH
Billiar, TR
Seol, DW
机构
[1] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA
[2] Chonbuk Natl Univ, Coll Vet Med, Biosafety Res Inst, Jeonju, Jeonbuk, South Korea
[3] Myongji Univ, Dept Sci Biol, Yongin, South Korea
[4] Chosun Univ, Sch Med, Dept Biochem, Kwangju, South Korea
关键词
D O I
10.1158/0008-5472.CAN-04-0284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The hypoxic environment in solid tumors results from oxygen consumption by rapid proliferation of tumor cells. Hypoxia has been shown to facilitate the survival of tumor cells and to be a cause of malignant transformation. Hypoxia also is well known to attenuate the therapeutic activity of various therapies in cancer management. These observations indicate that hypoxia plays a critical role in tumor biology. However, little is known about the effects of hypoxia on apoptosis, especially on apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a potent apoptosis inducer that has been shown to specifically limit tumor growth without damaging normal cells and tissues in vivo. To address the effects of hypoxia on TRAIL-induced apoptosis, HCT116 human colon carcinoma cells were exposed to hypoxic or normoxic conditions and treated with soluble TRAIL protein. Hypoxia dramatically inhibited TRAIL-induced apoptosis in HCT116 cells, which are highly susceptible to TRAIL in normoxia. Hypoxia increased antiapoptotic Bcl-2 family member proteins and inhibitors of apoptosis proteins. Interestingly, these hypoxia-increased antiapoptotic molecules were decreased by TRAIL treatment to the levels lower than those of the untreated conditions, suggesting that hypoxia inhibits TRAIL-induced apoptosis via other mechanisms rather than up-regulation of these antiapoptotic molecules. Additional characterization revealed that hypoxia significantly inhibits TRAIL-induced translocation of Bax from the cytosol to the mitochondria in HCT116 and A549 cells, with the concomitant inhibition of cytochrome c release from the mitochondria. Bax-deficient HCT116 cells were completely resistant to TRAIL regardless of oxygen content, demonstrating a pivotal role of Bax in TRAIL-induced apoptotic signaling. Thus, our data indicate that hypoxia inhibits TRAIL-induced apoptosis by blocking Bax translocation to the mitochondria, thereby converting cells to a Bax-deficient state.
引用
收藏
页码:4078 / 4081
页数:4
相关论文
共 39 条
[21]  
MURPHY BJ, 1994, CANCER RES, V54, P5808
[22]   Apoptosis by death factor [J].
Nagata, S .
CELL, 1997, 88 (03) :355-365
[23]   From bench to clinic with apoptosis-based therapeutic agents [J].
Nicholson, DW .
NATURE, 2000, 407 (6805) :810-816
[24]   Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex [J].
Pan, GH ;
O'Rourke, K ;
Dixit, VM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (10) :5841-5845
[25]   Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [J].
Park, SY ;
Billiar, TR ;
Seol, DW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 291 (01) :150-153
[26]   IFN-γ inhibition of TRAIL-induced IAP-2 upregulation, a possible mechanism of IFN-γ-enhanced TRAIL-induced apoptosis [J].
Park, SY ;
Billiar, TR ;
Seol, DW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 291 (02) :233-236
[27]  
Ravi R, 2002, CANCER RES, V62, P1583
[28]   Bax oligomerization in mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial protein [J].
Roucou, X ;
Montessuit, S ;
Antonsson, B ;
Martinou, JC .
BIOCHEMICAL JOURNAL, 2002, 368 :915-921
[29]   Mechanisms of cytochrome c release by proapoptotic BCL-2 family members [J].
Scorrano, L ;
Korsmeyer, SJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 304 (03) :437-444
[30]  
Seol DW, 2001, CANCER RES, V61, P1138